Search Results for "Juvisync"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Juvisync. Results 1 to 3 of 3 total matches.

Sitagliptin and Simvastatin (Juvisync)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011  (Issue 1377)
Sitagliptin and Simvastatin (Juvisync) ...
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).
Med Lett Drugs Ther. 2011 Nov 14;53(1377):89 |  Show IntroductionHide Introduction

Drug Interaction: Dabigatran (Pradaxa) and Statins

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
. Center for Drug Evaluation and Research. Juvisync (sitagliptin + simvastatin tablets). Clinical ...
The results of a recently published study suggest that taking the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa) with either simvastatin (Zocor, and others) or lovastatin (Altoprev, and others) increases the risk of major hemorrhage.
Med Lett Drugs Ther. 2017 Jan 30;59(1513):26 |  Show IntroductionHide Introduction

Alogliptin (Nesina) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 27, 2013  (Issue 1417)
in combination with simvastatin (Juvisync). 8. A dose of 50 mg once daily is recommended in patients with a CrCl ...
The FDA has approved the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment of type 2 diabetes. In addition to the single-ingredient product, the FDA also approved fixed-dose combinations of alogliptin/metformin (Kazano) and alogliptin/pioglitazone (Oseni) for the same indication. Alogliptin is the fourth DPP-4 inhibitor to become available in the US. The other three – saxagliptin (Onglyza), sitagliptin (Januvia), and linagliptin (Tradjenta) – are also available in fixed-dose combinations with metformin.
Med Lett Drugs Ther. 2013 May 27;55(1417):41-3 |  Show IntroductionHide Introduction